Micro Labs Usa, Inc.
Micro Labs USA, Inc. is the US marketing and distribution arm of Indian generics manufacturer Micro Labs Limited, selling FDA-approved generic oral, injectable, ophthalmic, and oral-solution medicines to US healthcare providers and pharmacies.
- Company typePrivate
- Founded1973
- HeadquartersSomerset, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Micro Labs Usa, Inc. does
Micro Labs USA, Inc. is a privately held US pharmaceutical marketing and distribution subsidiary headquartered at 220 Davidson Avenue, Suite 402, Somerset, New Jersey. It is a wholly owned subsidiary of Micro Labs Limited, an Indian pharmaceutical company founded in 1973 that ranks among the top twenty pharmaceutical companies in India (10th in prescriptions, 20th in sales domestically). The US entity markets and distributes a portfolio of FDA-approved generic medicines — including oral solid tablets and capsules, injections, ophthalmic solutions, and oral solutions — to healthcare providers, pharmacies, and patients across cardiovascular, diabetes, ophthalmic, respiratory, neurological, and anti-infective therapeutic areas.
The company does not manufacture in the United States; all products are produced at three USFDA-approved manufacturing facilities operated by the parent in India (one in Goa, two in Bangalore). Micro Labs USA's current portfolio includes 40+ FDA-approved generic products, with 25+ additional Abbreviated New Drug Applications (ANDAs) under FDA review and a stated pipeline ambition of 10–15 new ANDA filings per year. Selected products include Atorvastatin Calcium Tablets, Dorzolamide 2% ophthalmic solution, Dorzolamide-Timolol, Metformin Oral Solution, Clobetasol 0.05% Topical Solution, Amoxicillin formulations, Brivaracetam Injection, Bimatoprost Ophthalmic Solution, and Arformoterol Tartrate Inhalation Solution. The company is vertically integrated on Dorzolamide drug substance manufacturing, which provides cost and supply-chain advantages in the ophthalmic segment.
Micro Labs USA operates a B2B go-to-market model, selling generic pharmaceuticals to healthcare providers, pharmacy chains, and institutional buyers via direct field sales and standard pharmaceutical distribution channels, with pricing determined contractually and not publicly disclosed. Revenue is generated through unit-pricing on product sales (one-time/license model). Strategic growth has been pursued through two named US partnerships: with Saptalis Pharmaceuticals LLC (announced January 2020) covering oral liquids and topicals with planned launches totaling approximately $200 million in IQVIA-measured market opportunity, and with Armas Pharmaceuticals Inc. (announced May 2019) targeting multi-source injectables. Headcount at the US subsidiary is 11–50 employees, consistent with a lean marketing/distribution wrapper around the parent's much larger manufacturing and R&D infrastructure.
Micro Labs Usa, Inc. firmographics
Firmographics- Name
- Micro Labs Usa, Inc.
- Legal name
- Micro Labs USA, Inc.
- Website
- https://microlabsusa.com
- Company type
- Private
- Founded year
- 1973
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Micro Labs USA, Inc. is the US marketing and distribution arm of Indian generics manufacturer Micro Labs Limited, selling FDA-approved generic oral, injectable, ophthalmic, and oral-solution medicines to US healthcare providers and pharmacies.
- Ownership category
- akta.pro rank
Micro Labs Usa, Inc. industry classification
Industry- Product category
- Generic Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Generic Hospital & Institutional Products (HLAIABAL)
- akta.pro secondary industry
- Sterile Injectable Generics (HLAIABAC)
Keywords
Where Micro Labs Usa, Inc. is headquartered
LocationHeadquarters
- HQ city
- Somerset
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Micro Labs Usa, Inc. business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D, Infrastructure
Revenue model
- Generic Pharmaceutical Product Sales: Revenue generated from manufacturing and selling FDA-approved generic pharmaceutical products including oral tablets, capsules, injections, ophthalmic solutions, and oral solutions to healthcare providers and through pharmaceutical distribution channels
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Generic pharmaceutical products sold to healthcare providers and pharmacies |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Micro Labs Usa, Inc. product offering
Product offeringCore offering
Micro Labs USA markets and distributes a portfolio of FDA-approved generic pharmaceutical products in the U.S. market, including oral solid tablets and capsules, injectable medications, ophthalmic solutions, and oral solutions. Products span cardiovascular, antibiotic, anti-infective, respiratory, neurological, ophthalmic, and diabetes therapeutic categories and are manufactured in three USFDA-approved facilities operated by parent Micro Labs Limited in India.
Product overview
Micro Labs USA is a pharmaceutical company marketing a portfolio of FDA-approved generic medications across multiple dosage forms. The company offers oral solid tablets and capsules, injections, ophthalmic solutions, and oral solutions. Key products include cardiovascular medications (Atorvastatin Calcium, Amlodipine/Olmesartan), antibiotics (Amoxicillin products), respiratory treatments (Arformoterol), neurological medications (Brivaracetam, Aspirin/Dipyridamole), ophthalmic products (Bimatoprost, Dorzolamide), and diabetes treatments (Metformin). These products are manufactured in three USFDA-approved facilities in India (Goa and Bangalore) and distributed in the US market.
Differentiator
Problem solved
Functional benefit
Products and services
- Acetazolamide Extended-Release Capsules Extended-release capsules for treatment of certain conditions. Generic equivalent of Diamox Sequels.
- Amlodipine Besylate and Olmesartan Medoxomil Tablets Combination medication tablets for cardiovascular treatment. Generic equivalent of Azor.
- Amoxicillin and Clavulanate Potassium for Oral Suspension, USP Antibiotic oral suspension in two strengths (200 mg/28.5 mg per 5 mL and 400 mg/57 mg per 5 mL) for treating bacterial infections.
- Amoxicillin and Clavulanate Potassium Tablets, USP Antibiotic tablets available in multiple strengths (250/125 mg, 500/125 mg, 875/125 mg). Generic equivalent of Augmentin.
- Amoxicillin Capsules, USP Antibiotic capsules in 500 mg strength. Generic equivalent of Amoxil.
- Arformoterol Tartrate Inhalation Solution Inhalation solution for respiratory treatment (15 mcg/2 mL, 30 vials). Generic equivalent of Brovana.
- Aspirin and Extended-Release Dipyridamole Capsules Extended-release combination capsules (25 mg/200 mg) for antiplatelet therapy. Generic equivalent of Aggrenox.
- Atorvastatin Calcium Tablets Cholesterol management tablets available in 10 mg, 20 mg, 40 mg, and 80 mg strengths. Generic equivalent of Lipitor.
- Bimatoprost Ophthalmic Solution Ophthalmic solution (0.03%) for glaucoma treatment available in 2.5 mL, 5 mL, and 7.5 mL bottles. Generic equivalent of Lumigan.
- Brivaracetam Injection Antiepileptic injection (50 mg/5 mL). Generic equivalent of Briviact.
- Dorzolamide 2% Ophthalmic Solution Ophthalmic solution for glaucoma treatment. Company is vertically integrated with Dorzolamide drug substance.
- Dorzolamide-Timolol 22.3-6.8 mg/mL Ophthalmic Solution Combination ophthalmic solution for glaucoma treatment.
- Metformin Oral Solution 500 mg/5mL Oral solution (500 mg/5mL) indicated as adjunct to diet and exercise for glycemic control in adults and pediatric patients 10 years and older with type 2 diabetes. Only generic version of Riomet.
- Clobetasol 0.05% Topical Solution Topical solution for treatment of psoriasis and dermatitis. Generic equivalent of Clobex.
Quantifiable outcome
- $8.5 billion US Ophthalmic market presence established with launch of glaucoma drugs (Dorzolamide and Dorzolamide-Timolol)
- +1 more outcomes
Companies that use Micro Labs Usa, Inc.
Customer profileSegments1 record
Ideal customer profiles1 record
Micro Labs Usa, Inc. technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Micro Labs Usa, Inc. partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and flagship.
- Saptalis Pharmaceuticals LLCcoreStrategic collaboration between Micro Labs USA and Saptalis Pharmaceuticals to launch single-source and multisource generics in the United States. First product was Clobetasol 0.05% topical solution (generic of Clobetasol). The partnership covers oral liquid and topical products with planned launches totaling $200 million in market size (per IQVIA data). Saptalis brings formulation development expertise in liquid and semi-solid dosage forms.
- Armas Pharmaceuticals Inc.coreStrategic collaboration to bring select multisource injectable products to the U.S. market. This partnership expands Micro Labs' presence in the injectable generic pharmaceuticals segment. First products under this collaboration were select multisource injectable medications.
- Micro Labs LimitedflagshipMicro Labs USA, Inc. is a wholly owned subsidiary of Micro Labs Limited, India. Parent company founded in 1973, ranked among top 20 pharmaceutical companies in India (10th among prescriptions and 20th in sales in India local market). Provides manufacturing facilities (Goa and Bangalore), R&D capabilities, and corporate oversight.
Scale indicators5 records
Recent moves5 records
Expansion highlights6 records
Micro Labs Usa, Inc. competitors and assessment
Company assessmentBroad incumbents
- Endo International: US-based specialty and generics pharmaceutical company with overlapping generic injectable and oral solid portfolios. Comparable in the generic injectables and specialty generics segments, though broader in branded specialty.
- Sandoz (Novartis): Global generic and biosimilar leader spun out of Novartis. Overlaps with Micro Labs USA across generic oral solids, injectables, and ophthalmics, but operates at vastly larger scale and with broader geographic footprint.
- Teva Pharmaceutical Industries: World's largest generic pharmaceutical manufacturer, with a US-dominant generics business across all major therapeutic categories and dosage forms. Comparable portfolio breadth but at much larger scale and with broader specialty pharma exposure.
Direct peers
- Lupin Pharmaceuticals: Indian-headquartered generic pharmaceutical company with a US-focused subsidiary. Comparable product mix (oral solids, injectables, ophthalmics) and ANDA-driven US growth strategy.
- Aurobindo Pharma USA: US arm of Aurobindo Pharma, one of India's largest generic manufacturers. Directly comparable as an Indian-headquartered generic company with broad US generic portfolio across oral solids, injectables, and ophthalmics, with deep ANDA pipeline and USFDA-approved Indian facilities.
- Camber Pharmaceuticals: US generics subsidiary of Hetero Labs (India), focused exclusively on the US generic market. Closely comparable scale and operational model to Micro Labs USA, with similar ANDA-driven US generic strategy.
- Dr. Reddy's Laboratories: India-based global generic pharmaceutical manufacturer with significant US operations. Comparable as a vertically integrated Indian generic player with broad US ANDA pipeline, injectables, and ophthalmics portfolio.
- Glenmark Pharmaceuticals: India-based generic and specialty pharmaceutical company with a US subsidiary marketing generic oral solids and injectables. Similar model of Indian manufacturing feeding US distribution.
- Apotex Corp. Canadian-headquartered generic pharmaceutical manufacturer with major US operations. Comparable as a non-US-headquartered generic player serving the US market across oral solids, injectables, and ophthalmics.
- Zydus Pharmaceuticals USA: US subsidiary of India's Zydus Cadila, with comparable product breadth across cardiovascular, anti-infective, ophthalmic and other generic categories. Similar business model of leveraging parent manufacturing for US market.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Micro Labs Usa, Inc. social profiles
Digital presenceMicro Labs Usa, Inc. financial estimates
Financial estimateRevenue estimate
Valuation estimate
Micro Labs Usa, Inc. leadership team
Management profileNumber of profiles
Profiles1 record
Micro Labs Usa, Inc. funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Micro Labs Usa, Inc. M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Micro Labs Usa, Inc.
What does Micro Labs Usa, Inc. do?
Micro Labs USA markets and distributes a portfolio of FDA-approved generic pharmaceutical products in the U.S. market, including oral solid tablets and capsules, injectable medications, ophthalmic solutions, and oral solutions. Products span cardiovascular, antibiotic, anti-infective, respiratory, neurological, ophthalmic, and diabetes therapeutic categories and are manufactured in three USFDA-approved facilities operated by parent Micro Labs Limited in India.
Is Micro Labs Usa, Inc. a public or private company?
Micro Labs Usa, Inc. is a private company. It is classified as corporate owned and is currently operating.
When was Micro Labs Usa, Inc. founded?
Micro Labs Usa, Inc. was founded in 1973. It employs 11 to 50 people.
Where is Micro Labs Usa, Inc. based?
Micro Labs Usa, Inc. is headquartered in Somerset, United States, in the North America region.
How does Micro Labs Usa, Inc. make money?
One revenue line is on record: generic Pharmaceutical Product Sales.
Who are Micro Labs Usa, Inc.'s main competitors?
Broad incumbents on record are Endo International, Sandoz (Novartis) and Teva Pharmaceutical Industries. Direct peers are Lupin Pharmaceuticals, Aurobindo Pharma USA, Camber Pharmaceuticals, Dr. Reddy's Laboratories, Glenmark Pharmaceuticals, Apotex Corp. and Zydus Pharmaceuticals USA.
Does Micro Labs Usa, Inc. have an API?
No public API is recorded for Micro Labs Usa, Inc..
What industry is Micro Labs Usa, Inc. in?
Micro Labs Usa, Inc.'s product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIABAL, Generic Hospital & Institutional Products, with a secondary code of HLAIABAC, Sterile Injectable Generics. Its NAICS code is 325412 and its SIC code is 2834.